We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
- Authors
Fernández, Belén; Ordóñez, Antonio Jesús Lara; Fdez, Elena; Mutez, Eugénie; Comptdaer, Thomas; Leghay, Coline; Kreisler, Alexandre; Simonin, Clémence; Vandewynckel, Laurine; Defebvre, Luc; Destée, Alain; Bleuse, Séverine; Taymans, Jean-Marc; Chartier-Harlin, Marie-Christine; Hilfiker, Sabine
- Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD), and orally bioavailable, brain penetrant and highly potent LRRK2 kinase inhibitors are in early stages of clinical testing. Detection of LRRK2 phosphorylation, as well as phosphorylation of Rab10, a LRRK2 kinase substrate, have been proposed as target engagement biomarkers for LRRK2 inhibitor clinical trials. However, these readouts do not seem able to stratify patients based on enhanced LRRK2 kinase activity. Here, we describe a robust cell biological assay based on centrosomal cohesion alterations which were observed in peripheral blood mononuclear cellderived lymphoblastoid cell lines (LCLs) from patients with G2019S LRRK2 mutations as compared with healthy controls, and could also be detected in a subset of sporadic PD patient samples. We suggest that LCLs may be a valuable resource for LRRK2 research, and that determination of centrosomal cohesion deficits may assist in the stratification of a subset of sporadic PD patients.
- Subjects
LYMPHOBLASTOID cell lines; PARKINSON'S disease; DARDARIN; BIOLOGICAL assay; COHESION
- Publication
Biochemical Journal, 2019, Vol 476, Issue 19, p2797
- ISSN
0264-6021
- Publication type
Article
- DOI
10.1042/BCJ20190315